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The limited data regarding treatment of
inﬂammatory bowel disease (IBD) with
anI‐tumor necrosis factor anIbodies in
older paIents suggest equal eﬃcacy
but higher morbidity and mortality
compared to younger paIents. This
retrospecIve case control study aims to
clarify the eﬃcacy and safety of
inﬂiximab (IFX) in older IBD paIents.

Demographics

Adverse Events

Endoscopic Response

Methods
• IBD paIents ≥ 60 y.o. treated with
IFX at a single terIary IBD center
from 2006‐13 were idenIﬁed from
ICD‐9 codes.
• Study paIents were matched with
control IBD paIents <60 y.o. on sex,
IBD phenotype/locaIon and disease
duraIon.
• RetrospecIve chart review was
conducted to assess clinical and
endoscopic remission/response and
adverse events (AE) related to IFX.

• n= 33 pts ≥60 y.o. (study group); n= 33 pts
<60 y.o. (control group)
• Sex (each group): 20 women, 13 men
• Age: x̄ = 70.6 (60‐83 ) vs. 40.6 (23‐59)
• IBD type (each group): CD n=16 (48.5%),
UC n=16 (48.5%), indeterminate coliIs n=1 (3%)
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Clinical Eﬃcacy
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• Total AEs (related to IFX): 11 study pts
(33.3%) vs. 13 control pts (39.4%), p<.80
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• Remission = 1) Physician’s global assessment
(PGA) 2) No pain meds/steroids/addiIonal
IBD meds 3) No hospitalizaIons/surgeries.
 10 study pts (30.3%) vs. 4 control pts
(12.1%), p<.13
• Response = Sx improvement (PGA).
 8 study pts (24.2%) vs. 18 control pts
(54.5%), p<.02

• Endoscopic Improvement:
5/19 study pts (26.3%) vs. 10/20 control
pts (50%), p<.91
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• Endoscopic Remission:
5/19 study pts (26.3%) vs. 2/20 control
pts (10%), p<.24
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• Serious AEs: 6 study pts (42.9%) vs. 3
control pts (17.7%), p<.23.
• Serious AEs included infecIons requiring
hospitalizaIon, congesIve heart failure,
lupus‐like reacIon, and malignancy

• IBD paIents ≥ 60 years old treated with
IFX have similar rates of clinical
remission but lower rates of clinical
response compared to younger paIents.
• The rate of AEs was similar in older and
younger paIents.
• RetrospecIve study /small sample size
limit data interpretaIon.

Future Direc<ons
• Control for age‐related morbidity by
studying older IBD pts treated with
medical therapy other than IFX

